Faron Pharmaceuticals Oy (LON:FARN – Get Rating) shares passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of GBX 176.78 ($2.08) and traded as high as GBX 239 ($2.81). Faron Pharmaceuticals Oy shares last traded at GBX 232.50 ($2.73), with a volume of 30,156 shares traded.
Faron Pharmaceuticals Oy Stock Performance
The company has a market capitalization of £143.53 million and a P/E ratio of -6.48. The business has a 50-day moving average of GBX 176.78 and a 200-day moving average of GBX 197.63. The company has a debt-to-equity ratio of 121.51, a current ratio of 1.70 and a quick ratio of 1.09.
Faron Pharmaceuticals Oy Company Profile
(Get Rating)
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies.
Further Reading
- Power Integrations Stock Can Power Your Portfolio
- Don't Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe's?
- Agilent Remains In Buy Range Ahead Of Next Week's Q4 Report
- Three Penny Stocks Making Big Moves In November
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.